Healthcare
Live Price
Offline$2.85
-1.38% today
1Y Change
+67.05%
Window
Jun 26, 2025 → Jun 24, 2026
Coverage: 249 bars · Jun 26, 2025 → Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Nkarta, Inc. (NKTX) is a Healthcare stock with a market cap of $210.00M and listed on NASDAQ. The stock last traded around $2.85 and up 67.1% across the available one-year price window (Jun 26, 2025 → Jun 24, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +11.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +11.9%, free cash flow +13.6% with operating margin 0.0% and ROIC -31.4%. Stock Foundry combines NKTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NKTX
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NKTX Max Drawdown
-34.22%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for NKTX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$86.1M
+24.4% YoY
Free Cash Flow
-$73.0M
+29.9% YoY
Revenue Growth
+0.0%
EPS Growth
+11.9%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -9M | 0 | -6M | 0 | 0 |
| Operating Income | -121M | -128M | -132M | -119M | -86M |
| EBITDA | -112M | -119M | -120M | -116M | -85M |
| Net Income | -104M | -109M | -118M | -114M | -86M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 40M | 28M | 31M | 37M | 61M |
| Total Assets | 404M | 501M | 379M | 473M | 274M |
| Total Liabilities | 92M | 93M | 106M | 101M | 23M |
| Shareholder Equity | 312M | 408M | 273M | 372M | 251M |
| Total Debt | 76M | 80M | 88M | 83M | 12M |
| Net Debt | 37M | 52M | 57M | 45M | -48M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
68M
-19.2% YoY
Capital Expenditures
5M
+89.3% YoY
Free Cash Flow
73M
+29.9% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-30.0%
Debt / Equity
0.24x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.